Introducing Spravato (Esketamine) nasal spray
We are excited to introduce SPRAVATO:
The First NMDA Receptor Antagonist Approved, in Conjunction with Oral Antidepressant,
for Adults with Treatment-Resistant Depression
• Treatments must be given twice weekly weeks 1-4, weekly weeks 5-8,
and weekly or every other week for week 9 and following.
• Patients must be monitored for 2 hours after receiving the spray.